Sat Kartar Life Warrants Issue (16 Nov 2026)
Sat Kartar Life Ltd allot 5.5 lakh convertible warrants at ₹172 each on 16 Nov 2026
Sat Kartar Life · Pharmaceuticals & Biotechnology
Key highlights
- Allotment of 5,50,000 fully convertible warrants to promoters at ₹172 per warrant (₹162 premium) approved
- Subscription amount of ₹2.37 crore (25%) received; balance ₹7.10 crore payable on conversion within 18 months
- Warrants convertible into equal number of equity shares by 15 May 2028; allotted to Manprit Singh Chadha, Archana Chadha, Simrati Kaur
Original filing
Allotment of Securities
Read the filing on NSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Engineering Services
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Sat Kartar Life
- Fundraise / allotmentSat Kartar Life Limited allots 5.5 lakh convertible warrants on preferential basis
- Fundraise / allotmentNotableSat Kartar Life Limited receives NSE approval for 5,50,000 convertible warrants issue
- Fundraise / allotmentNotableSat Kartar Life Limited held Extra-Ordinary General Meeting on October 23, 2026
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentAegis LogisticsAegis Logistics issues 2.89 crore equity shares via QIP at ₹1,210 each
- Fundraise / allotmentAegis LogisticsAegis Logistics Limited issues 2.89 crore equity shares via qualified institutions placement
- Fundraise / allotmentBajaj FinanceBajaj Finance Limited closes QIP issue of 114.15 million equity shares on Nov 16, 2026
- Fundraise / allotmentAegis LogisticsAegis Logistics approves closure of qualified institutions placement of equity shares
- Fundraise / allotmentSML MahindraSML Mahindra Limited announces Rs. 1450 crore rights issue to fund MTBD acquisition
- Fundraise / allotmentSML MahindraSML Mahindra Limited approves Rights Issue to raise up to ₹1450 crore
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.
